Articles On Patrys (ASX:PAB)

Chinese shoppers have not lost their appetite for EZZ’s health and beauty products Ho-Ho-Ho (Chi Minh)! Viet deal is an early Xmas prez for Truscreen holders Patrys says it will focus on its Plan B drug candidate   China is a tough consum...

Highlights    Enhanced understanding of SCLC subtypes drives tailored treatment approaches.   Immunotherapy and antibody-drug conjugates emerge as key strategies.   Asia-Pacific region identified as a critical area for further clinica...

ASX starts week lower with mining stocks under pressure Resolute mining plunges after CEO detained in Mali Bitcoin surges past US$81k as Trump’s win fuels optimism   The ASX had a rough start to the week, with mining stocks dragging the m...

ASX rallies broadly as tech stocks lead Commonwealth Bank hits record, Neuren jumps Asian markets rise, China stimulus eyed   The ASX was riding the coattails of a strong Wall Street session, with tech stocks leading the charge.  At the c...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

The S&P/ASX 200 fell 1.3% in October with small cap companies outperforming S&P Dow Jones Indices said financials led the gains in October and is up 30% YTD Ovanti rose 525% in October after appointment of former Zip US CFO Simon K...

ASX opens November lower, led by financial sector sell-off Macquarie Group fell after profit decline Ironbark Zinc jumps 75% on new leadership   The ASX kicked off November with a thud, sliding about 0.5%. This  follows a tough session o...

  ASX slips  amid earnings updates and company meetings AGL drops over 6pc after downgrade, while Origin Energy rises Talga surges after Sweden approves graphite mine   The ASX slipped by 0.22% after being dragged by a flurry of company...

ASX rises  following Wall Street’s lead Cettire drops 12pc after disappointing earnings update Retail house Premier Investments surge after potential Myer deal   The ASX rose by 0.34% on Tuesday following Wall Street’s lead. Consumer dis...

ASX gains  as energy and mining stocks rally Arcadium Lithium surges  after Rio acquisition, while GYG reports strong Q1 Hurricane Milton lands and pushes oil prices higher   The ASX gained ground by 0.3% on Thursday and neared its recor...

ASX fell as mining stocks dropped on China’s lack of stimulus Brent oil dipped below US$80 Big lithium stocks fall, but smaller players keep gaining after Rio Tinto’s Arcadium takeover talks   The ASX closed lower by 0.35% in a volatile...

  ASX 200 index falls despite gains in energy stocks Smaller oil and gas firms benefit from rising crude prices Iron ore stocks drop as prices retreat   The ASX 200 index fell hard on Friday, down by 0.75%, despite some gains in the Ener...

    ASX edges down in a quiet market Pilbara Minerals falls 5pc as share block sale is reported Westpac sells auto finance unit for up to $1.6 billion   The ASX has lifted slightly on Thursday, up by 0.1%, as traders remain cautious amid...

Good morning, and welcome to Stockhead’s Top 10 at somewhere near 11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

  ASX flattish amid rising Middle East tensions Crude oil prices surge 5pc, pushing oil stocks higher Gold miners gain as investors seek safe havens   The ASX shifted from early gains to a mostly flat finish as investors turned to safer...

Argent Biopharma packs its bags for London on a one-way ticket Patrys shares slump 50% on cancellation of key drug program Painchek targets US market for its pain detection app   Health Check is renowned biotech journo Tim Boreham’s daily...

Good morning, and welcome to Stockhead’s Top 10 at somewhere near 11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX200 hits record high driven by US Fed interest rate cut Mining stocks surge as iron ore prices rebound ALS shares drop 10pc, Monadelphous rises on new contracts   The ASX200 hit yet another record high today, boosted by the first inte...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

ASX up as earnings season rolls on; Origin down 10pc, Telstra up 3pc Australia’s unemployment rate edged up to 4.2pc from 4.1pc Iron ore futures dropped below US$94 per ton   The ASX edged slightly higher by 0.1% on Thursday, boosted by a...

ASX rises circa 0.5pc Consumer stocks in focus this week SGQ and PHX lead small caps   Aussie stocks have closed higher on Monday as IT and retail stocks added strength to sentiment. The S&P/ASX200 closed higher, gaining 36.00 points...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Good morning, and welcome to Stockhead’s Top 10 at shortly-after-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the t...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

The ASX200 closed +0.5% higher on Tuesday on the back of a big lift in the Mining sector.  Lithium stocks led, with IGO (ASX:IGO) and Pilbara (ASX:PLS) gaining around 3%.  Iron ore miners  rallied after the Nymex CFR China, 62% Fe price swu...

Patrys (ASX: PAB) has released positive data from pre-clinical studies using deoxymabs PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. The therapeutic antibody developme...

Patrys’ deoxymabs data on vasculitis disease presented Next Science’s BLASTX data published   Patrys’ deoxymabs data presented Patrys (ASX:PAB) jumped 12% this morning after announcing that new data from preclinical studies using PAT-DX1...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

  Local markets started slow before ripping into an all-time intraday high  10 of 11 sectors higher, benchmark closes 0.50pc up Small Caps led by Motio, Cue Energy and Sierra Rutile   Some strong earnings on the last day of February and...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix   The ASX200 is up +0.4% at  the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...